These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32183586)

  • 1. Safety of two-hour intermittent intravenous infusions of tacrolimus in the allogeneic hematopoietic stem cell transplantation unit.
    Bacopoulos AJ; Ho L; Yang A; Ng P; Dara C; Loach D; Deotare U; Michelis FV; Viswabandya A; Kim DD; Lipton JH; Messner HA; Thyagu S
    J Oncol Pharm Pract; 2021 Jan; 27(1):33-39. PubMed ID: 32183586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation.
    Woo M; Przepiorka D; Ippoliti C; Warkentin D; Khouri I; Fritsche H; Körbling M
    Bone Marrow Transplant; 1997 Dec; 20(12):1095-8. PubMed ID: 9466284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interdisciplinary implementation of tacrolimus intravenous standard concentration in hematopoietic stem cell transplantation recipients.
    Shank BR; Deaver M; Baker A; Myers AL; Zhang YP; Anderegg B; Bassett R; Westmoreland M
    J Oncol Pharm Pract; 2018 Jul; 24(5):365-370. PubMed ID: 28554241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twice daily i.v. bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation.
    Skeens M; Pai V; Garee A; Termuhlen AM; Bajwa RP; Gross TG; Soni S
    Bone Marrow Transplant; 2012 Nov; 47(11):1415-8. PubMed ID: 22484323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.
    Furlong T; Storb R; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan K; Witherspoon R; Nash RA
    Bone Marrow Transplant; 2000 Nov; 26(9):985-91. PubMed ID: 11100278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with optimized tacrolimus dosing in hematopoietic stem cell transplantation.
    Butts AR; Brown VT; McBride LD; Bolaños-Meade J; Bryk AW
    J Oncol Pharm Pract; 2016 Apr; 22(2):275-83. PubMed ID: 25802301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors.
    Mori T; Kato J; Shimizu T; Aisa Y; Nakazato T; Yamane A; Ono Y; Kunimoto H; Okamoto S
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):229-34. PubMed ID: 21708109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transitioning tacrolimus to sirolimus in allogeneic hematopoietic cell transplantation.
    Arrabi L; Jan A; Hosing C; Milton DR; Yeh J
    Eur J Haematol; 2021 Dec; 107(6):634-641. PubMed ID: 34431142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders.
    Ringdén O; Remberger M; Dahllöf G; Garming-Legert K; Karlsson H; Svenberg P; Uhlin M; Uzunel M; Mattsson J
    Eur J Haematol; 2011 Dec; 87(6):503-9. PubMed ID: 22974354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation.
    Jacobson P; Uberti J; Davis W; Ratanatharathorn V
    Bone Marrow Transplant; 1998 Aug; 22(3):217-25. PubMed ID: 9720734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation.
    Yamashita T; Fujishima N; Miura M; Niioka T; Abumiya M; Shinohara Y; Ubukawa K; Nara M; Fujishima M; Kameoka Y; Tagawa H; Hirokawa M; Takahashi N
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):111-8. PubMed ID: 27217047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.
    Törlén J; Ringdén O; Garming-Legert K; Ljungman P; Winiarski J; Remes K; Itälä-Remes M; Remberger M; Mattsson J
    Haematologica; 2016 Nov; 101(11):1417-1425. PubMed ID: 27662016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low incidence of acute graft-versus-host disease with short-term tacrolimus in haploidentical hematopoietic stem cell transplantation.
    Gao L; Liu J; Zhang Y; Chen X; Gao L; Zhang C; Liu Y; Kong P; Zhong J; Sun A; Du X; Su Y; Li H; Liu H; Peng X; Zhang X
    Leuk Res; 2017 Jun; 57():27-36. PubMed ID: 28273549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twice-daily intravenous bolus tacrolimus infusion: A safe and effective regimen for graft-versus-host disease prophylaxis.
    Hashmi H; Bhandari S; Kumar R; Tripathi P; Rhodes JB; Figg L; Baize T; Krem MM; Hegazi M; Emmons R
    Hematol Oncol Stem Cell Ther; 2020 Dec; 13(4):232-237. PubMed ID: 32413417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation.
    Yanik G; Levine JE; Ratanatharathorn V; Dunn R; Ferrara J; Hutchinson RJ
    Bone Marrow Transplant; 2000 Jul; 26(2):161-7. PubMed ID: 10918426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of continuous and twice-daily infusions of cyclosporine A for graft-versus-host-disease prophylaxis in pediatric hematopoietic stem cell transplantation.
    Umeda K; Adachi S; Tanaka S; Ogawa A; Hatakeyama N; Kudo K; Sakata N; Igarashi S; Ohshima K; Hyakuna N; Chin M; Goto H; Takahashi Y; Azuma E; Koh K; Sawada A; Kato K; Inoue M; Atsuta Y; Takami A; Murata M;
    Pediatr Blood Cancer; 2015 Feb; 62(2):291-298. PubMed ID: 25307105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial tacrolimus weight-based dosing strategy in allogeneic hematopoietic stem-cell transplantation.
    Soskind R; Xiang E; Lewis T; Al-Homsi AS; Papadopoulos J; Cirrone F
    J Oncol Pharm Pract; 2021 Sep; 27(6):1447-1453. PubMed ID: 32957861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis.
    Piñana JL; Perez-Pitarch A; Garcia-Cadenas I; Barba P; Hernandez-Boluda JC; Esquirol A; Fox ML; Terol MJ; Queraltó JM; Vima J; Valcarcel D; Ferriols-Lisart R; Sierra J; Solano C; Martino R
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1177-1185. PubMed ID: 28396159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcineurin inhibitor-induced irreversible neuropathic pain after allogeneic hematopoietic stem cell transplantation.
    Fujii N; Ikeda K; Koyama M; Aoyama K; Masunari T; Kondo E; Matsuzaki T; Mizobuchi S; Hiraki A; Teshima T; Shinagawa K; Ishimaru F; Tanimoto M
    Int J Hematol; 2006 Jun; 83(5):459-61. PubMed ID: 16787880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.